Biliverdin, a
heme metabolite, has been previously reported to alleviate cerebral ischemic
reperfusion injury (CIRI). However, the alterations of brain
proteome profiles underlying this treatment remain elusive. The objective of this study is to analyze the differential
protein expression profile in cerebral cortex of rats involved in anti-CIRI effects of
Biliverdin, providing experimental foundation for searching specific marker
proteins. Rat model of MCAO/R was established, HE staining, TTC staining, TUNEL staining, and neurological behavioral examination, corner turning test, adhesive removal test, were performed to validate the effects of
Biliverdin, and the results indicated that
Biliverdin plays a significant role in alleviating CIRI. Furthermore, proteomic analysis of brain tissues of rats subjected to CIRI following
Biliverdin treatment was performed using an integrated TMT-based quantitative proteomic approach coupled with LC-MS/MS technology to clarify the comprehensive mechanisms of
Biliverdin in CIRI. First, we conducted strict quality control data for TMT experiments. Finally, a total of 7366
proteins were identified, of which 95
proteins were differentially expressed (DEPs) between the CIRI group and the
Sham group and 52 between the CIRI and BV groups. In addition, two overlapping
proteins among the 147 DEPs, Atg4c and Camlg, were validated by RT-qPCR and western blotting, and their levels were consistent with the results of TMT analysis. Taken together, the current findings firstly mapped comprehensive proteomic changes after CIRI treated with
Biliverdin, providing a foundation for developing potentially therapeutic targets of anti-CIRI of
Biliverdin and clinically prognostic
biomarkers of
stroke.